FMP
Avid Bioservices, Inc.
CDMO
NASDAQ
Inactive Equity
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
12.49 USD
0 (0%)
Historical Prices
From:
To:
About
ceo
Mr. Nicholas Stewart Green B.Sc., MBA
sector
Healthcare
industry
Biotechnology
website
https://www.avidbio.comexchange
NASDAQ
Description
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characte...
CIK
0000704562
ISIN
US05368M1062
CUSIP
05368M106
Address
2642 Michelle Drive
Phone
714 508 6100
Country
US
Employee
371
IPO Date
Apr 4, 1994
Financial Statement
Earnings
CDMO Financial Summary
CIK
0000704562
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
05368M106
ISIN
US05368M1062
Country
US
Price
12.49
Beta
1.41
Volume Avg.
1.58M
Market Cap
798.9M
Shares
-
52-Week
5.9-12.51
DCF
17.37
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-5.18
P/B
-
Website
https://www.avidbio.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CDMO News
Alex Lavoie
Dec 30, 2024
Avid Bioservices, Inc. (NASDAQ: CDMO) Under Investigation Am...
Avid Bioservices, Inc. (NASDAQ: CDMO) is under scrutiny as Halper Sadeh LLC investigates the fairness of its proposed sale to GHO Capital Partners LLP and Ampersand Capital Partners. The deal offers $12.50 per share in cash, raising concerns about whether the board has secured the best possible outcome for shareholders. The law firm is known for representing investors affected by securities fraud and corporate misconduct. The investigation by Halper Sadeh LLC is particularly relevant given rece...
Tony Dante
Sep 8, 2024
Avid Bioservices, Inc. (NASDAQ:CDMO) Achieves Record Financi...
Avid Bioservices, Inc. (NASDAQ:CDMO) has been making significant strides in the biopharmaceutical sector as a contract development and manufacturing organization. Since its rebranding from Peregrine Pharmaceuticals, Inc. in January 2018, CDMO has focused on producing biopharmaceutical drug substances, leveraging mammalian cell culture technology. This specialization places Avid Bioservices in a unique position within the biotechnology and biopharmaceutical industries, catering to a growing deman...
Andrew Wynn
Jul 4, 2024
Avid Bioservices, Inc. Reports Mixed Financial Results for Q...
On Wednesday, July 3, 2024, Avid Bioservices, Inc. (NASDAQ:CDMO) reported its earnings per share (EPS) for the fourth quarter of the fiscal year 2024, revealing a figure of -1.94. This result was significantly below the anticipated -0.038, indicating a larger-than-expected loss for the period. However, the company's revenue for the same period was $42.98 million, which slightly exceeded the forecast of $42.14 million. This mixed financial outcome highlights the challenges and opportunities facin...
Seeking Alpha
Apr 29, 2024
Avid Bioservices, Inc. (CDMO) Q3 2024 Earnings Call Transcri...
Avid Bioservices, Inc. (NASDAQ:CDMO ) Q3 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Tim Brons – Investors Relations Group Nick Green – President and Chief Executive Officer Dan Hart – Chief Financial Officer Matt Kwietniak – Chief Commercial Officer Conference Call Participants Jacob Johnson – Stephens Sean Dodge – RBC Capital Markets Matt Hewitt – Craig-Hallum Capital Group Max Smock – William Blair Paul Knight – KeyBanc Operator Good day, ladies and gentlemen,...
InvestorPlace
Mar 7, 2024
Why Is Avid Bioservices (CDMO) Stock Down 30% Today?
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Thursday after the contract development and manufacturing company announced the pricing of a private placement. The private placement includes 7.00% Convertible Senior Notes due 2029 with an aggregate principal amount of $160 million.
Seeking Alpha
Jan 7, 2024
Avid Bioservices: Don't Miss The Bigger Picture
Avid Bioservices has invested heavily in building new facilities, causing lower margins and negative free cash flow. The company's recent expansion projects have increased its revenue capacity to $400 million, with expected adjusted EBITDA margins in the low to mid 30s. Despite the investments, the company's guidance for the current fiscal year implies limited growth due to a shift in project types and the new facility not being fully operational yet.
InvestorPlace
Dec 8, 2023
Why Is Avid Bioservices (CDMO) Stock Down 18% Today?
Avid Bioservices (NASDAQ: CDMO ) stock is falling on Friday following the release of its earnings report for its fiscal second quarter of 2024. Avid Bioservices reported adjusted earnings per share of -12 cents alongside revenue of $25.4 million.
InvestorPlace
Dec 7, 2023
CDMO Stock Earnings: Avid Bioservices Misses EPS, Misses Rev...
Avid Bioservices (NASDAQ: CDMO ) just reported results for the second quarter of 2024. Avid Bioservices reported earnings per share of -12 cents.
